Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tezepelumab

- PMLiVE

Amgen decision on brodalumab unsettles anti-IL-17 class

Move made following data found linking the drug to suicidal thoughts

Amgen appoints Jonathan Graham general counsel and secretary

He will succeed David Scott who is retiring

- PMLiVE

Allergy specialist Circassia buys asthma firms

British-based company acquires Sweden’s Aerocrine and privately held Prosonix

- PMLiVE

AZ links with Abbott on personalised asthma diagnostic

Diagnostic would aim to identify patients most likely to respond to tralokinumab

- PMLiVE

Novartis biosimilar blocked by US court

Swiss firm’s Neupogen copy has its injunction upheld at appeal

- PMLiVE

Prescribing costs jump in England

New report finds that asthma and diabetes drugs the most costly to the NHS

- PMLiVE

FDA clears Advair follow up Breo for asthma

But respiratory drug given the thumbs up for adults only

- PMLiVE

FDA panel backs Amgen’s T-Vec for melanoma

Approved by a panel of 22 to one despite questions on its impact on survival

- PMLiVE

Amgen starts shipping Corlaner in US

Firm also reports healthy financial growth in the first quarter

- PMLiVE

FDA clears Amgen’s Corlaner for heart failure

It is the firm’s first cardiovascular product to gain approval

- PMLiVE

AstraZeneca and EHR firm to use drug alert system

Firm will team up with Practice Fusion to help keep patients on the right treatment pathway

- PMLiVE

Amgen gets EU nod for wider use of Vectibix

US biotech’s cancer therapy can now be used in a first-line setting

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links